• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

复发缓解型多发性硬化症中持续性残疾进展与功能系统评分的关系:四项随机临床试验安慰剂数据的分析。

Relationship between sustained disability progression and functional system scores in relapsing-remitting multiple sclerosis: analysis of placebo data from four randomized clinical trials.

机构信息

Allegheny General Hospital, Pittsburgh, Pa., USA.

出版信息

Neuroepidemiology. 2015;44(1):16-23. doi: 10.1159/000369621. Epub 2015 Jan 23.

DOI:10.1159/000369621
PMID:25634764
Abstract

BACKGROUND

The Expanded Disability Status Scale (EDSS), based on different functional system scores (FSS), remains the most frequently used disability assessment in relapsing-remitting multiple sclerosis (RRMS). In this analysis, we evaluated the relationship between sustained disability progression, measured by EDSS, and simultaneous changes in individual FSS domains.

METHODS

A post hoc analysis was performed on data from placebo-treated RRMS patients from four large, randomized, multicenter, phase 3 clinical trials. Sustained disability progression was defined as a ≥1.0-point EDSS score increase over a ≥3- or ≥6-month period. Simultaneous sustained disability progression and worsening of individual FSS domains was analyzed.

RESULTS

The majority of patients experienced sustained disability progression and simultaneous worsening of ≥1 FSS domain, with ≥1-point worsening in the pyramidal domain being most frequently associated with sustained disability progression (in 31-51% of patients), followed by ≥1-point worsening in the cerebellar (35-41% of patients) and sensory (31-45% of patients) domains.

CONCLUSION

The key FSS components correlating with sustained disability progression, measured by EDSS, appear to be pyramidal, cerebellar, and sensory. In this analysis, the simultaneous worsening of consistent FSS domains confirms the validity and reliability of the use of sustained EDSS progression as a measure of disability progression.

摘要

背景

扩展残疾状况量表(EDSS)基于不同的功能系统评分(FSS),仍然是最常用于复发缓解型多发性硬化症(RRMS)的残疾评估方法。在这项分析中,我们评估了 EDSS 测量的持续性残疾进展与个体 FSS 域同时变化之间的关系。

方法

对来自四项大型、随机、多中心、3 期临床试验的安慰剂治疗 RRMS 患者的数据进行了事后分析。持续性残疾进展定义为 EDSS 评分在≥3 个月或≥6 个月期间增加≥1.0 分。分析了同时发生的持续性残疾进展和个体 FSS 域的恶化。

结果

大多数患者经历了持续性残疾进展和≥1 个 FSS 域的同时恶化,其中以锥体域≥1 点恶化与持续性残疾进展最相关(在 31%-51%的患者中),其次是小脑域≥1 点恶化(在 35%-41%的患者中)和感觉域≥1 点恶化(在 31%-45%的患者中)。

结论

与 EDSS 测量的持续性残疾进展相关的关键 FSS 成分似乎是锥体、小脑和感觉。在这项分析中,一致的 FSS 域的同时恶化证实了使用持续 EDSS 进展作为残疾进展衡量标准的有效性和可靠性。

相似文献

1
Relationship between sustained disability progression and functional system scores in relapsing-remitting multiple sclerosis: analysis of placebo data from four randomized clinical trials.复发缓解型多发性硬化症中持续性残疾进展与功能系统评分的关系:四项随机临床试验安慰剂数据的分析。
Neuroepidemiology. 2015;44(1):16-23. doi: 10.1159/000369621. Epub 2015 Jan 23.
2
Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients.阿仑单抗可改善初治复发缓解型多发性硬化症患者的神经功能系统。
J Neurol Sci. 2016 Apr 15;363:188-94. doi: 10.1016/j.jns.2016.02.025. Epub 2016 Feb 12.
3
Assessing disability progression with the Multiple Sclerosis Functional Composite.使用多发性硬化功能综合评分评估残疾进展情况。
Mult Scler. 2009 Aug;15(8):984-97. doi: 10.1177/1352458509106212.
4
Functional system scores provide a window into disease activity occurring during a multiple sclerosis treatment trial.功能系统评分提供了一个了解多发性硬化症治疗试验期间疾病活动情况的窗口。
Neurol Res. 2011 Jun;33(5):549-52. doi: 10.1179/1743132810Y.0000000017.
5
Natalizumab treatment shows low cumulative probabilities of confirmed disability worsening to EDSS milestones in the long-term setting.在长期治疗环境中,那他珠单抗治疗显示出确认残疾恶化到 EDSS 里程碑的累积概率较低。
Mult Scler Relat Disord. 2018 Aug;24:11-19. doi: 10.1016/j.msard.2018.04.020. Epub 2018 May 2.
6
Relapses and subsequent worsening of disability in relapsing-remitting multiple sclerosis.复发缓解型多发性硬化症的复发及随后残疾状况的恶化
Neurology. 2006 Sep 12;67(5):804-8. doi: 10.1212/01.wnl.0000234064.17156.03.
7
Disability outcome measures in therapeutic trials of relapsing-remitting multiple sclerosis: effects of heterogeneity of disease course in placebo cohorts.复发缓解型多发性硬化症治疗试验中的残疾结局指标:安慰剂队列中疾病进程异质性的影响
J Neurol Neurosurg Psychiatry. 2000 Apr;68(4):450-7. doi: 10.1136/jnnp.68.4.450.
8
Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.甲泼尼龙联合干扰素β-1a 治疗复发缓解型多发性硬化症(MECOMBIN 研究):一项多中心、双盲、随机、安慰剂对照、平行分组试验。
Lancet Neurol. 2010 Jul;9(7):672-80. doi: 10.1016/S1474-4422(10)70132-0. Epub 2010 Jun 9.
9
Sustained improvement in Expanded Disability Status Scale as a new efficacy measure of neurological change in multiple sclerosis: treatment effects with natalizumab in patients with relapsing multiple sclerosis.扩展残疾状态量表的持续改善作为多发性硬化症神经学变化的新疗效指标:那他珠单抗治疗复发型多发性硬化症患者的疗效。
Mult Scler. 2011 Aug;17(8):970-9. doi: 10.1177/1352458511399611. Epub 2011 Mar 18.
10
Change in quality of life in patients with relapsing-remitting multiple sclerosis over 2 years in relation to other clinical parameters: results from a trial of intramuscular interferon {beta}-1a.在一项肌内注射干扰素 β-1a 的试验中,2 年内复发缓解型多发性硬化症患者的生活质量变化与其他临床参数的关系。
Mult Scler. 2011 Jun;17(6):734-42. doi: 10.1177/1352458510397221. Epub 2011 Feb 7.

引用本文的文献

1
AI-assisted identification of disability patterns within identical EDSS grades.人工智能辅助识别相同扩展残疾状态量表(EDSS)等级内的残疾模式。
Mult Scler. 2025 May;31(6):677-688. doi: 10.1177/13524585251327300. Epub 2025 Apr 18.
2
Correspondence of MRI and nTMS With EDSS in Multiple Sclerosis: Longitudinal Follow-Up Study.多发性硬化症中MRI和nTMS与扩展残疾状态量表(EDSS)的相关性:纵向随访研究
Ann Clin Transl Neurol. 2025 Jun;12(6):1240-1255. doi: 10.1002/acn3.70041. Epub 2025 Apr 17.
3
Expression of CD40 and CD192 in Classical Monocytes in Multiple Sclerosis Patients Assessed with Transcranial Magnetic Stimulation.
经颅磁刺激评估的多发性硬化症患者经典单核细胞中CD40和CD192的表达
Biomedicines. 2023 Oct 23;11(10):2870. doi: 10.3390/biomedicines11102870.
4
Subtypes of relapsing-remitting multiple sclerosis identified by network analysis.通过网络分析确定的复发缓解型多发性硬化症亚型。
Front Digit Health. 2023 Jan 11;4:1063264. doi: 10.3389/fdgth.2022.1063264. eCollection 2022.
5
Assessment of Motor Evoked Potentials in Multiple Sclerosis.多发性硬化症中的运动诱发电位评估。
Sensors (Basel). 2023 Jan 2;23(1):497. doi: 10.3390/s23010497.
6
Confirmed disability progression as a marker of permanent disability in multiple sclerosis.确认残疾进展为多发性硬化症永久性残疾的标志物。
Eur J Neurol. 2022 Aug;29(8):2321-2334. doi: 10.1111/ene.15406. Epub 2022 Jun 9.
7
Peginterferon beta-1a reduces disability worsening in relapsing-remitting multiple sclerosis: 2-year results from ADVANCE.聚乙二醇干扰素β-1a可降低复发缓解型多发性硬化症患者的残疾恶化程度:ADVANCE研究的2年结果
Ther Adv Neurol Disord. 2017 Jan;10(1):41-50. doi: 10.1177/1756285616676065. Epub 2016 Nov 16.